Results 91 to 100 of about 2,015,869 (349)

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

open access: yesMolecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed   +8 more
wiley   +1 more source

Conformance test suite for implementations of the security protocol suite IPsec v2

open access: yesТруды Института системного программирования РАН, 2018
The paper presents conformance test suite for new Internet Protocol Security Suite IPsec v2. The test suite was constructed by means of the UniTESK automated testing technology and its implementation, CTESK toolkit.The work was done in the Institute for ...
A. V. Nikeshin   +2 more
doaj  

Loss of primary cilia promotes EphA2‐mediated endothelial‐to‐mesenchymal transition in the ovarian tumor microenvironment

open access: yesMolecular Oncology, EarlyView.
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho   +11 more
wiley   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

open access: yesMolecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau   +9 more
wiley   +1 more source

A Model to Estimate First-Order Mutation Coverage from Higher-Order Mutation Coverage

open access: yes, 2016
The test suite is essential for fault detection during software development. First-order mutation coverage is an accurate metric to quantify the quality of the test suite. However, it is computationally expensive.
Demeyer, Serge   +2 more
core   +1 more source

Notules Ichthyologiques (suite)

open access: yes, 1944
(Uploaded by Plazi from the Biodiversity Heritage Library) No abstract provided.
openaire   +6 more sources

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

open access: yesMolecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp   +13 more
wiley   +1 more source

Automatic Repair of Real Bugs: An Experience Report on the Defects4J Dataset

open access: yes, 2015
Defects4J is a large, peer-reviewed, structured dataset of real-world Java bugs. Each bug in Defects4J is provided with a test suite and at least one failing test case that triggers the bug.
Durieux, Thomas   +4 more
core   +1 more source

A First-Order Logic Formalization of the Industrial Ontology Foundry Signature Using Basic Formal Ontology [PDF]

open access: yes, 2019
Basic Formal Ontology (BFO) is a top-level ontology used in hundreds of active projects in scientific and other domains. BFO has been selected to serve as top-level ontology in the Industrial Ontologies Foundry (IOF), an initiative to create a suite of ...
Ameri, Farhad   +6 more
core  

Home - About - Disclaimer - Privacy